Neumora Therapeutics IPO Presentation Deck

Advancing Our Neuroscience Pipeline • Targeting novel mechanisms across a broad range of neuropsychiatric and neurodegenerative indications Broad pipeline addressing some of the most prevalent brain health disorders • Scaling pipeline through internal discovery efforts and business development activities ● ● Multiple clinical trial initiations planned in 2023/2024 Strong IP with worldwide rights to all programs Pipeline Indications: 60M Total addressable U.S. population 1,2,3 7 Development programs PROGRAM Target/Mechanism Neuropsychiatry Programs Navacaprant (NMRA-140) KOR Antagonist NMRA-511 V1aR Antagonist NMRA-266 M4R Modulator NMRA-CK18 CK18 Inhibitor INDICATION US Prevalence NMRA-NLRP3 NLRP3 Inhibitor NMRA-GCASE GCASE Activator Major Depressive Disorder 21M Bipolar Depression 7M Agitation in Alzheimer's Disease 6M NMRA-NMDA NMDA Modulator Neurodegeneration Programs Schizophrenia 3M Schizophrenia 3M ALS/Alzheimer's Disease 25K/6M Parkinson's Disease 1M Parkinson's Disease 1M 1) National Institute of Mental Health, 2021. 2) National Alliance of Mental Illness, 2017. 3) Figure includes total adressable U.S. population across all neurophsychiatric and neurodegenerative indications Preclinical Phase 1 Phase 2 Phase 3 ANTICIPATED PROGRAM MILESTONES . Initiate KOASTAL-1 (3Q23), KOASTAL-2 (1Q24), KOASTAL-3 (4Q23) and KOASTAL-LT (2H23) Studies Topline data from KOASTAL-1 (2H24) Initiate clinical study in bipolar depression (1H24) Initiate clinical study in Alzheimer's disease agitation (1H24) File IND with the FDA (4Q23) Continue to advance preclinical development Continue to advance preclinical development Continue to advance preclinical development Continue to advance preclinical development Confidential 7

View entire presentation